Lilly's Verzenio gets first-line EU approval for HER2- advanced breast cancer

07:06 EDT 3 Oct 2018 | Pharmafile

The European Medicines Agency has confirmed its approval of Eli Lilly’s CDK4/6 inhibitor Verzenio (ademaciclib), it has emerged.

The therapy has been authorised in the first-line treatment of hormone receptor-positive (HR+), epidermal growth factor receptor 2 negative (HER2-) locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant, as well as a second-line treatment after earlier endocrine drugs.

Lilly's Verzenio gets first-line EU approval for HER2- advanced breast cancer

The European Medicines Agency has confirmed its approval of Eli Lilly’s CDK4/6 inhibitor Verzenio (ademaciclib), it has emerged.

More From BioPortfolio on "Lilly's Verzenio gets first-line EU approval for HER2- advanced breast cancer"